Capillary leak syndrome natural history, complications and prognosis: Difference between revisions

Jump to navigation Jump to search
Line 12: Line 12:
The second phase results in the recruitment of the initially extravasated fluid. Intravascular overload with [[polyuria]] and [[pulmonary edema]] often occur. Edema may be more severe due to massive fluid supply in the initial phase. It's necessary to monitor the patient in order to switch to depletion treatment with [[diuretics]] or [[hemofiltration]].
The second phase results in the recruitment of the initially extravasated fluid. Intravascular overload with [[polyuria]] and [[pulmonary edema]] often occur. Edema may be more severe due to massive fluid supply in the initial phase. It's necessary to monitor the patient in order to switch to depletion treatment with [[diuretics]] or [[hemofiltration]].


{{Family tree/start}}
{{Family tree | | | | | | | | | | | | | A01 | | | | | | | A01= '''Primary MR'''}}
{{Family tree | | | | | | | | | | | | | |!| | | | | | | | }}
{{Family tree | | | | | | | | | | | | | B01 | | | | | | | B01= [[Mitral regurgitation stages#Primary Mitral Regurgitation Stages|What is the severity of MR]]? }}
{{Family tree | | | | | | | |,|-|-|-|-|-|^|-|-|-|-|-|.| |}}
{{Family tree | | | | | | | C01 | | | | | | | | | | C02 | C01= '''Severe MR''' <br><div style="float: left; text-align: left; width:15em ">
❑ Severe MVP with loss of coaptation <br>
❑ RHD with loss of central coaptation<br>
❑ Left ventricular dilation <br>
❑ Regurgitation fraction ≥ 50% <br>
❑ Regurgitation volume ≥ 60ml <br>
❑ Effective regurgitation orifice ≥ 0.4cm² <br>
❑ Vena contracta ≥ 0.7cm </div>| C02= '''Progressive MR'''<br> ''(Stage B)'' <br><div style="float: left; text-align: left; width:15em ">
❑ Severe MVP with normal coaptation <br>
❑ RHD with normal coaptation <br>
❑ No Left ventricular dilation <br>
❑ Regurgitation fraction < 50% <br>
❑ Regurgitation volume < 60ml <br>
❑ Effective regurgitation orifice < 0.4cm² <br>
❑ Vena contracta < 0.7cm </div>}}
{{Family tree | | | | | | | |!| | | | | | | | | | | |!|}}
{{Family tree | | | | | | | D00 | | | | | | | | | | |!| D00= Is the patient symptomatic?}}
{{Family tree | | | |,|-|-|-|^|-|-|-|.| | | | | | | |!| }}
{{Family tree | | | D01 | | | | | | D02 | | | | | | |!| D01= Yes <br> ''([[Mitral regurgitation stages#Primary Mitral Regurgitation Stages|Stage D]])''| D02= No <br> ''([[Mitral regurgitation stages#Primary Mitral Regurgitation Stages|Stage C]])''}}
{{Family tree | | | |!| | | |,|-|-|-|+|-|-|-|.| | | |!| }}
{{Family tree | | | E01 | | E02 | | E03 | | E04 | | |!| E01= Is the [[LVEF]]>30%?| E02= [[LVEF]] 30-60% <br> OR <br> LVESD≥40 mm <br> ''([[Mitral regurgitation stages#Primary Mitral Regurgitation Stages|Stage C2]])''| E03= [[LVEF]]>60% <br> AND <br> LVESD<40 mm <br> ''([[Mitral regurgitation stages#Primary Mitral Regurgitation Stages|Stage C1]])''| E04= New onset [[atrial fibrillation]]<br> OR <br> PASP>50 mmHg <br> ''([[Mitral regurgitation stages#Primary Mitral Regurgitation Stages|Stage C1]])''}}
{{Family tree | |,|-|^|-|.| |!| | | | |!| |!| | | | |!| }}
{{Family tree | |!| | | |!| |!| | | | | F00 | | | | |!| F00= <div style="float: left; text-align: left; width:15em ">Is the likelihood of success for the valve repair >95% and the expected mortality <1%? </div>}}
{{Family tree | |!| | | |!| |!| | |,|-|-|^|-|.| | | |!| }}
{{Family tree | F01 | | F02 |!| | F03 | | | F04 | | |!| F01= No| F02= Yes| F03= Yes| F04= No}}
{{Family tree | |!| | | | |!|!| | |!| | | | |!| | | |!| }}
{{Family tree | G01 | | | G02 | | G03 | | | G04 | | G05 | G01= [[Mitral valve surgery]] ([[ACC AHA guidelines classification scheme#Classification of Recommendations|Class IIb]])| G02= [[Mitral valve surgery]] ([[ACC AHA guidelines classification scheme#Classification of Recommendations|Class I]])| G03= [[Mitral valve repair]] ([[ACC AHA guidelines classification scheme#Classification of Recommendations|Class IIa]])|G04= Periodic monitoring| G05= Periodic monitoring}}
{{Family tree/end}}
===Indications for Surgery in Chronic Secondary Mitral Regurgitation===
Shown below is an algorithm depicting the indications for mitral valve surgery or period monitoring among patients with chronic secondary MR according to the 2014 AHA/ACC guideline for the management of patients with valvular heart disease.<ref name="pmid24603192">{{cite journal| author=Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP, Guyton RA et al.| title=2014 AHA/ACC guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. | journal=J Am Coll Cardiol | year= 2014 | volume= 63 | issue= 22 | pages= 2438-88 | pmid=24603192 | doi=10.1016/j.jacc.2014.02.537 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24603192  }} </ref>  Note that when [[mitral valve surgery]] is indicated, [[mitral valve repair]] is preferred over [[mitral valve replacement]] whenever feasible.<ref name="pmid24603192">{{cite journal| author=Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP, Guyton RA et al.| title=2014 AHA/ACC guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. | journal=J Am Coll Cardiol | year= 2014 | volume= 63 | issue= 22 | pages= 2438-88 | pmid=24603192 | doi=10.1016/j.jacc.2014.02.537 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24603192  }} </ref>
<span style="font-size:85%">'''Abbreviations:''' '''MR:''' mitral regurgitation</span>
{{Family tree/start}}
{{Family tree | | | | | A01 | | | | | A01= Secondary MR and patient is receiving medical therapy}}
{{Family tree | | | | | |!| | | | | | }}
{{Family tree | | | | | A02 | | | | A02= [[Mitral regurgitation stages#Secondary Mitral Regurgitation Stages|What is the severity of MR]]?}}
{{Family tree | |,|-|-|-|+|-|-|-|.| | }}
{{Family tree | B01 | | B02 | | B03 | | B01= Symptomatic ([[New york heart association functional classification|NYHA class III-IV]]) severe MR <br> ''([[Mitral regurgitation stages#Secondary Mitral Regurgitation Stages|Stage D]])'' | B02= Asymptomatic severe MR <br> ''([[Mitral regurgitation stages#Secondary Mitral Regurgitation Stages|Stage C]])'' | B03= Progressive MR <br> ''([[Mitral regurgitation stages#Secondary Mitral Regurgitation Stages|Stage B]])''}}
{{Family tree | |!| | | |!| | | |!| | | }}
{{Family tree | C01 | | C02 | | C03 | | C01= [[Mitral valve surgery]] ([[ACC AHA guidelines classification scheme#Classification of Recommendations|Class IIb]])| C02= Periodic monitoring| C03= Periodic monitoring}}
{{Family tree/end}}


==Complications==
==Complications==

Revision as of 02:58, 7 August 2022

Capillary leak syndrome Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating Capillary leak syndrome from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT Scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Surgery

Medical Therapy

Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Capillary leak syndrome natural history, complications and prognosis On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Capillary leak syndrome natural history, complications and prognosis

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Capillary leak syndrome natural history, complications and prognosis

CDC on Capillary leak syndrome natural history, complications and prognosis

Capillary leak syndrome natural history, complications and prognosis in the news

Blogs on Capillary leak syndrome natural history, complications and prognosis

Directions to Hospitals Treating Capillary leak syndrome

Risk calculators and risk factors for Capillary leak syndrome natural history, complications and prognosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: M. Hassan, M.B.B.S

Overview

Natural History

The episode usually consists of two phases

The Capillary Leak Phase (1-4 days)

The initial phase is the capillary leak phase, lasting from 1 to 4 days. Clinical features are abdominal pain, nausea, generalized edema and hypotension that may result in cardiopulmonary collapse. Acute renal failure is due to acute tubular necrosis consequent to hypovolemia and rhabdomyolysis.

Recruitment of the Interstitial Fluid

The second phase results in the recruitment of the initially extravasated fluid. Intravascular overload with polyuria and pulmonary edema often occur. Edema may be more severe due to massive fluid supply in the initial phase. It's necessary to monitor the patient in order to switch to depletion treatment with diuretics or hemofiltration.

 
 
 
 
 
 
 
 
 
 
 
 
Primary MR
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
What is the severity of MR?
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Severe MR

❑ Severe MVP with loss of coaptation
❑ RHD with loss of central coaptation
❑ Left ventricular dilation
❑ Regurgitation fraction ≥ 50%
❑ Regurgitation volume ≥ 60ml
❑ Effective regurgitation orifice ≥ 0.4cm²

❑ Vena contracta ≥ 0.7cm
 
 
 
 
 
 
 
 
 
Progressive MR
(Stage B)

❑ Severe MVP with normal coaptation
❑ RHD with normal coaptation
❑ No Left ventricular dilation
❑ Regurgitation fraction < 50%
❑ Regurgitation volume < 60ml
❑ Effective regurgitation orifice < 0.4cm²

❑ Vena contracta < 0.7cm
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Is the patient symptomatic?
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Yes
(Stage D)
 
 
 
 
 
No
(Stage C)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Is the LVEF>30%?
 
LVEF 30-60%
OR
LVESD≥40 mm
(Stage C2)
 
LVEF>60%
AND
LVESD<40 mm
(Stage C1)
 
New onset atrial fibrillation
OR
PASP>50 mmHg
(Stage C1)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Is the likelihood of success for the valve repair >95% and the expected mortality <1%?
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
No
 
Yes
 
 
 
Yes
 
 
No
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mitral valve surgery (Class IIb)
 
 
Mitral valve surgery (Class I)
 
Mitral valve repair (Class IIa)
 
 
Periodic monitoring
 
Periodic monitoring

Indications for Surgery in Chronic Secondary Mitral Regurgitation

Shown below is an algorithm depicting the indications for mitral valve surgery or period monitoring among patients with chronic secondary MR according to the 2014 AHA/ACC guideline for the management of patients with valvular heart disease.[1] Note that when mitral valve surgery is indicated, mitral valve repair is preferred over mitral valve replacement whenever feasible.[1]

Abbreviations: MR: mitral regurgitation

 
 
 
 
Secondary MR and patient is receiving medical therapy
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
What is the severity of MR?
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Symptomatic (NYHA class III-IV) severe MR
(Stage D)
 
Asymptomatic severe MR
(Stage C)
 
Progressive MR
(Stage B)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mitral valve surgery (Class IIb)
 
Periodic monitoring
 
Periodic monitoring
 

Complications

Most common complications of capillary leak syndrome include the following:[2][3]

Complications of Capillary Leak Syndrome

Prognosis

Mortality is reported in 21% of the 57 cases described. However, better management of this condition has recently led to lower mortality.

In the Mayo Clinic’s experience, the median survival of 25 patients that were followed over 30 years (counting only SCLS-related deaths) was approximately 15 years, and their 5-year survival rate was 76%. In European experience, the 5-year post-diagnosis survival rate was 85% in 23 patients who had received prophylactic treatment and 20% in 5 patients who had not. However, better identification and management of this condition appears to be resulting in lower mortality and improving survival and quality-of-life results as of late.

References

  1. 1.0 1.1 Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP, Guyton RA; et al. (2014). "2014 AHA/ACC guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines". J Am Coll Cardiol. 63 (22): 2438–88. doi:10.1016/j.jacc.2014.02.537. PMID 24603192.
  2. Hajare KR, Patil P, Bansode J (2018). "Idiopathic Systemic Capillary Leak Syndrome". Indian J Crit Care Med. 22 (5): 369–371. doi:10.4103/ijccm.IJCCM_464_17. PMC 5971649. PMID 29910550.
  3. Kapoor P, Greipp PT, Schaefer EW, Mandrekar SJ, Kamal AH, Gonzalez-Paz NC; et al. (2010). "Idiopathic systemic capillary leak syndrome (Clarkson's disease): the Mayo clinic experience". Mayo Clin Proc. 85 (10): 905–12. doi:10.4065/mcp.2010.0159. PMC 2947962. PMID 20634497.


Template:WikiDoc Sources